Skip to main content

Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.

Publication ,  Journal Article
Vaishnavi, S; Gadde, K; Alamy, S; Zhang, W; Connor, K; Davidson, JRT
Published in: J Clin Psychopharmacol
August 2006

Atypical depression, with features of hypersomnia, hyperphagia, anergia, and rejection sensitivity, is a common presentation of major depressive disorder. There are few available effective therapies for this disorder. We test modafinil, a novel wake-promoting agent, as monotherapy for atypical depression in a double-blind, placebo-controlled, relapse prevention trial after open-label treatment. We found that modafinil significantly improved atypical depression symptoms during 12 weeks of open-label treatment (mean +/- SD Hamilton Depression Scale (29-item version) score changed from 34 +/- 8.2 at baseline to 9.7 +/- 9.3, P < 0.0001), and that benefits were maintained alike in both the continuation and placebo arms during the double-blind treatment phase (P = 0.92). Modafinil was well tolerated and the drug was associated with significant weight loss compared with placebo (P = 0.01).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Psychopharmacol

DOI

ISSN

0271-0749

Publication Date

August 2006

Volume

26

Issue

4

Start / End Page

373 / 378

Location

United States

Related Subject Headings

  • Withholding Treatment
  • Weight Loss
  • Treatment Outcome
  • Time Factors
  • Thirst
  • Psychiatry
  • Patient Selection
  • Patient Dropouts
  • Nausea
  • Modafinil
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaishnavi, S., Gadde, K., Alamy, S., Zhang, W., Connor, K., & Davidson, J. R. T. (2006). Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol, 26(4), 373–378. https://doi.org/10.1097/01.jcp.0000227700.263.75.39
Vaishnavi, Sandeep, Kishore Gadde, Sayed Alamy, Wei Zhang, Kathryn Connor, and Jonathan R. T. Davidson. “Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.J Clin Psychopharmacol 26, no. 4 (August 2006): 373–78. https://doi.org/10.1097/01.jcp.0000227700.263.75.39.
Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JRT. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol. 2006 Aug;26(4):373–8.
Vaishnavi, Sandeep, et al. “Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.J Clin Psychopharmacol, vol. 26, no. 4, Aug. 2006, pp. 373–78. Pubmed, doi:10.1097/01.jcp.0000227700.263.75.39.
Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JRT. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol. 2006 Aug;26(4):373–378.

Published In

J Clin Psychopharmacol

DOI

ISSN

0271-0749

Publication Date

August 2006

Volume

26

Issue

4

Start / End Page

373 / 378

Location

United States

Related Subject Headings

  • Withholding Treatment
  • Weight Loss
  • Treatment Outcome
  • Time Factors
  • Thirst
  • Psychiatry
  • Patient Selection
  • Patient Dropouts
  • Nausea
  • Modafinil